AVASTIN 25 MG
BEVACIZUMAB : 25 MG · DIN 02270994 · HOFFMANN-LA ROCHE LIMITED
Health Canada status: MARKETED
What is AVASTIN?
AVASTIN 25 MG contains BEVACIZUMAB : 25 MG. It is listed in the Health Canada Drug Product Database under DIN 02270994, held by HOFFMANN-LA ROCHE LIMITED, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 02-Nov-2005. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is AVASTIN used for?
AVASTIN (bevacizumab for injection) is indicated for: • Metastatic Colorectal Cancer (mCRC) - Avastin in combination with fluoropyrimidine-based chemotherapy is indicated for first-line treatment of patients with metastatic carcinoma of the colon or rectum. • Locally Advanced, Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) - Avastin, in combination with carboplatin/paclitaxel chemotherapy regimen, is indicated for treatment of patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer. • Platinum-Sensitive Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer - Avastin, in combination with carboplatin and gemcitabine is indicated for the treatment of patients with first recurrence platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancer. • Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer - Avastin in combination with paclitaxel, topotecan or pegylated liposomal doxorubicin is indicated for the treatment of patients with recurrent, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens. • Malignant Glioma (WHO Grade IV) – Glioblastoma - Avastin, in combination with lomustine, is indicated for the treatment of patients with glioblastoma after relapse or disease progression, following prior therapy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02270994 |
|---|---|
| Brand name | AVASTIN |
| Generic / active ingredient | BEVACIZUMAB : 25 MG |
| Manufacturer | HOFFMANN-LA ROCHE LIMITED |
| Strength | 25 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Schedule D |
| ATC code | L01FG01 BEVACIZUMAB |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 02-Nov-2005 |
How is it stored and handled?
null
How is it supplied?
Available in packs of 1 vial.
What can be used instead?
Other Canadian products sharing ATC code L01FG01 BEVACIZUMAB. 13 of 13 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ABEVMY | 100 MG / 4 ML | SOLUTION | BIOSIMILAR COLLABORATIONS IRELAND LIMITED | MARKETED | DIN 02522179 |
| ABEVMY | 400 MG / 16 ML | SOLUTION | BIOSIMILAR COLLABORATIONS IRELAND LIMITED | MARKETED | DIN 02522160 |
| AYBINTIO | 100 MG / 4 ML | SOLUTION | SAMSUNG BIOEPIS CO., LTD | MARKETED | DIN 02522829 |
| AYBINTIO | 400 MG / 16 ML | SOLUTION | SAMSUNG BIOEPIS CO., LTD | MARKETED | DIN 02522837 |
| BAMBEVI | 100 MG / 4 ML | SOLUTION | APOTEX INC | MARKETED | DIN 02520729 |
| BAMBEVI | 400 MG / 16 ML | SOLUTION | APOTEX INC | MARKETED | DIN 02520737 |
| MVASI | 25 MG | SOLUTION | AMGEN CANADA INC | MARKETED | DIN 02470748 |
| MVASI | 25 MG | SOLUTION | AMGEN CANADA INC | MARKETED | DIN 02470756 |
| VEGZELMA | 100 MG / 4 ML | SOLUTION | CELLTRION INC. | MARKETED | DIN 02534177 |
| VEGZELMA | 400 MG / 16 ML | SOLUTION | CELLTRION INC. | MARKETED | DIN 02534185 |
Who else supplies BEVACIZUMAB worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. BEVACIZUMAB appears in 120 registered pack listings across 10 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.